BERTIS

"MASTOCHECK," which is an integration of the core technologies of Bertis, was recognized for its excellence and obtained a product license from the the Ministry of Food and Drug Safety(MFDS) in 2019 as an algorithmic medical device that uses multiple markers. Furthermore, the product obtained the New Excellent Technology (NET) certification from the Ministry of Health and Welfare in the medical science field for the first time in 10 years... We have a core technology platform that cover the overall processes starting from the discovery of protein biomarkers to the development of diagnostic solutions. Based on this, research and development are being conducted on diagnostic solutions for cancers and major diseases. While global proteomics companies do not have commercially available disease diagnosis products to date (as of August 2023), Bertis successfully commercialized "MASTOCHECK," a breast cancer blood test that utilizes proteomics technologies, in 2019 for the first time in the..

Also known as: Bertis Inc.